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uncontroled BP or TC was 46.4% and 48.7%, respectively. The
correction of the logistic model demonstrated the association of
CVD with male sex (OR = 2.6), diabetes (OR = 2.2), dyslipi-
demia (OR = 1.6), BP (OR = 1.3) and age (OR = 1.1), p < 0.05.
CONCLUSIONS: Therapeutic control goals in primary care
setting might be improved. It would be necessary to make new
representative studies showing the degree of control of our
patients in daily clinical practice.
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OBJECTIVES: A recent Pan-European Survey highlighted a
prevalence of low High Density Lipoprotein-cholesterol (HDL-c
<1.03 mmol/L in men and <1.29 mmol/l in women) in over 30%
of patients diagnosed with dyslipidemia, irrespective of statin
treatment. In order to help physicians focus their attention on
this risk factor, a model was used to project clinical beneﬁts on
coronary heart disease (CHD) endpoints of raising HDL-c by
adding Niaspan® to statin therapy in Type 2 Diabetes (T2D)
patients. METHODS: A computer model simulated the clinical
beneﬁt of combination therapy statin + Niaspan®; the ﬁrst sub-
model (Monte-Carlo simulation) generated a cohort using
patient characteristics from the Pan-European Survey (diabetic
sub-group) and applied Niaspan® treatment effect (European
SPC, 2 g/day); the second sub-model (Markov) estimated the
long-term clinical outcomes associated with patient’s lipid
changes (Framingham risk equations). Simulations were run to
capture 5, 10 years and patients’ lifetimes. RESULTS: In these
patients, mean life expectancies of 19.42 years and 18.78 years
were projected for the statin + Niaspan® and statin monother-
apy arms respectively (difference of 0.64 years). The addition of
Niaspan® to statin treatment was associated with a lower cumu-
lative incidence of CHD events than statin monotherapy at dif-
ferent time horizons leading to absolute risk reductions of 14.1%
for myocardial infarction and 5.5% for CHD death. CON-
CLUSIONS: Due to its positive effect on HDL-c levels, the addi-
tion of Niaspan® to statin treatment was projected to reduce 
the cumulative incidence of CHD events compared to statin
monotherapy in a European T2D patient population with per-
sistently low HDL-c.
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OBJECTIVES: Thiazolidinedione (TZD) was recommended not
for patients with moderate and serious heart failures due to the
adverse reaction of body ﬂuid retention. Our study investigated
the use of TZD by type 2 diabetic patients after they were dis-
charged from hospitalizations for heart failure. METHODS: The
cohort observation was based on claims database of Taiwan’s
National Health Insurance (NHI) for 2002∼2004. There were
4774 diabetic patients who were hospitalized due to heart failure
during 2003: 379 TZD users and 4395 non-TZD users. A total
of 2692 non-TZD users who used sulfonylurea after discharge
were selected as the control group. Cox proportional hazard
models were estimated to compared the outcomes of death and
readmission to hospitals of TZD users and sulfonylurea users,
one year after the time patients were discharged. RESULTS:
There were 7.9% of diabetic patients who were hospitalized for
heart failure and received TZD treatments. There was no signif-
icant difference on readmission over one year after discharge
between the two groups. However, among those who used TZD
or sulfonylurea less than 60 days, those who used TZD had
lower HR of readmission than those who used sulfonylurea (HR
0.728, 95% CI 0.551∼0.962). Overall, the HR for death among
patients receiving TZD was signiﬁcant lower than the control
group of sulfonylurea users (HR 0.092, 95% CI = 0.022–0.380).
CONCLUSIONS: Based on the precautions stated in TZD
package inserts, 7.9% of type 2 diabetic patients with heart
failure received potentially inappropriate prescriptions. Short
term use of TZD signiﬁcantly reduced hazards ratio in readmis-
sion, though long term use of both TZD and sulfonylurea
showed no difference on readmission, and the use of TZD sig-
niﬁcantly reduced the hazard of death.
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OBJECTIVES: Changing patterns of immunosuppression use
have been associated with increased risk of adverse graft and
patient survival outcomes. This study aimed to assess the rela-
tionship between discontinuing use of mycophenolate mofetil
(MMF) on two-year graft loss and two-year patient death.
METHODS: US claims data from commercial health plans for
396 patients receiving heart transplants (1995–2005) were
linked to data from the Organ Procurement Transplant Network
(OPTN). Transplant recipients were grouped into two: those
who continued and those who discontinued (MMF DC) using
MMF. MMF use was deﬁned as having ≥1 pharmacy claim post-
transplant for the medication. Discontinuation was deﬁned as
more than a 30 day gap in MMF coverage followed by no sub-
sequent reﬁlls during the year following the initial MMF script.
Cox proportional hazards analysis was used to estimate the risk
of discontinuing MMF on graft loss and dying. RESULTS: Thir-
teen percent (N = 52) of the study population was in the MMF
DC group. The majority of the population was between age 41
and 60 (57%), male (78%), transplanted between 1996–2000
(44%), and received a medication for a gastrointestinal condi-
tion during the year following their initial MMF script (65%).
Discontinuing use of MMF was associated with an increased risk
of graft loss (Hazard Ratio [HR] = 3.45 p = 0.04) and an
increased risk of death (HR = 2.79, p = 0.01) compared to con-
tinued MMF use during the year of follow-up. CONCLUSIONS:
Disrupting the pattern of MMF use was related to a signiﬁcant
increase in the risk of graft loss and death during two years post
transplant in this heart transplant recipient population covered
by commercial health plans. Future work should examine
whether these ﬁndings extend to heart transplant recipients
covered by other types of insurance and potential causes of
therapy discontinuation.
